AU620448B2 - Process for the micronization of glibenolamide - Google Patents

Process for the micronization of glibenolamide Download PDF

Info

Publication number
AU620448B2
AU620448B2 AU42302/89A AU4230289A AU620448B2 AU 620448 B2 AU620448 B2 AU 620448B2 AU 42302/89 A AU42302/89 A AU 42302/89A AU 4230289 A AU4230289 A AU 4230289A AU 620448 B2 AU620448 B2 AU 620448B2
Authority
AU
Australia
Prior art keywords
glibenclamide
acid
water
salt
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42302/89A
Other versions
AU4230289A (en
Inventor
Ottmar Jaenicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6364187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU620448(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU4230289A publication Critical patent/AU4230289A/en
Application granted granted Critical
Publication of AU620448B2 publication Critical patent/AU620448B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A process for preparing a micronised form of glibenclamide of the formula <IMAGE> with a BET surface area of the active compound particles of at least 3 m<2>/g is described. It entails a suspension of a sparingly soluble salt of glibenclamide in water being acidified with an acid. The result is a microfine precipitate of glibenclamide.

Description

TjiE COMMISSIONER OF PATENTS.
COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952-69 6 2 0 4 4 8 COMPLETE St-JECIFICATION
(ORIGINAL)
Application Number: Lodged: Class I t. Class 'Corplete Specifi!cation Lodged: Accepted: Published: 0.: 1io1ity:.
.00 Related Art: .006 ar~me of Applicant: i4dress of Applicant Actual Inventor Address for Service HOECHST AKTIENGESELLSCHAFT 50 Bruningstrasse, D-6230 Frankfurt/Main 80, Federal Republic of Germany OGlIAR JAENICKE X~WWDWUMSatermark Patent Trademark Attorneys 50 QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.
Complete Specification for the invention entitled: PROCESS FOR THE MICRONIZATION OF GLIBENCLAMVIDE The following statement is a full description of this invention, including the best methtod of performing it known to HOECHST AKTIENGESELLSCHAFT Dr.D/gm HOE 88/F 274 Description Process for the micronization of glibenclamide Glibenclamide,a sulfonylurea derivative of the formula
OCH
3
CONHCH
2 CH2-(Q -50NHCNH-
CI
is an oral antidiabetic which is particularly suitable for the treatment of Diabetes melitus for example, German Patent 1,301,812).
It is known that, given the low solubility of glibenclamide in the digestive juices, the absorption rate depends .0 on the degree of distribution of the active compound So*. (German Patent 2,348,334, corresponding to US Patents 3,979,520 and 4,060,634). Very small particle sizes in the order of 2 pm with a surface area of at least 3 m 2 /g by the BET method offer the advantage of a high absorption rate which results in a therapeutically desirable rapid drop in the blood sugar level.
o S* Various processes are known from the literature for the preparation of glibenclamid having large surface areas in the range from 3 to 10 m 2 /g by the BET method. German Patent 2,348,334 describes methods for the microprecipitation of glibenclamide starting from glibenclamide SJ or salts of glibenclamide.
Microfine glibenclamid is obtained in accordance with the prior art indicated, for example by precipitating the active compound from a water-miscible organic solvent. In this case, glibenclamide is dissolved, for example, in dimethylformamide, and the solution is run into water or water/acid mixtures with vigorous stirring. To achieve better mixing, it is proposed to run or pump the solution i ii 2 directly into the stirring head of an Ultra-Turrax turbine stirrer.
Alternatively, the sodium salt of glibenclamide can be dissolved in a mixture of methanol and water. After filtration, the solution is metered into water to which the amount of acid necessary for neutralization of the sodium salt has been added. To ensure good mixing, an Ultra-Turrax turbine stirrer is likewise employed.
As a further variant, the use of aqueous solutions of the alkali metal salt of glibenclamide is proposed. The low solubility of the alkali metal salts in water is disadvantageous, which means that the use of aqueous solutions for microprecipitation is not a useful industrial process.
A further way of micronizing is fine grinding of glibenco* lamide.In order to achieve the high surface areas of up to 10 m 2 /g which are desired, repeated grinding in jet mills is necessary, possibly also with addition of grinding auxiliaries.
RO Patent 89,209 (cf. Chemical Abstracts 107, 28393g (1987)) describes another variant for the preparation of microfine glibenclamide having particles of 1-2 pm.
Glibenclamide is dissolved in dimethylformamide, and the solution at 80-85 0 C is added to initially introduced water 25 or the water is added to the hot solution.
From various points of view, these methods representing the prior art have disadvantages in an economic respect, as far as quality is concerned, or regarding the technical complexity.
In the case of microprecipitation in accordance with the prior art using organic solvents, side reactions of glibenclamide with the solvents cannot be avoided. The permissible concentrations of byproducts in pharmaceuti- 3 cal active compounds such as glibenclamide are very low.
In BP 80, the level of secondary compounds, such as the sulfonamide (4-[2-(5-chloro-2-methoxybenzamido)ethyl]phenylsulfonamide) or the urethane (methyl chloro-2-methoxybenzamido)ethyl]phenylsulfonylcarbamate) is limited at less than 0.4 Persons skilled in the art know that re-cleavage to form the sulfonamide occurs as a function of the temperature, in the order of some tenths of a percent even at 40° 60 0 C, on dissolution of glibenclamide in dimethylformamide. If glibenclamid is dissolved in methanol, a urethane is formed, as is known, and can reach concentrations of some tenths of a percent over a period of a few hours in the temperature range from 40° 60 0
C.
«b S Since the temperatures before complete dissolution of glibenclamide inDMF, methanol or methanol/water mixtures are in the range from 400 60 0 C in the case of the S. concentrations which are necessary for industrial processes, a drop in the quality of glibenclamide in these precipitation processes cannot be excluded, even if very careful procedures are followed.
A further disadvantage of these precipitation processes is the additional costs incurred on disposal of the organic solvents, whether by recycling, combustion or biodegradation in the treatment plant.
The residual levels of solvents in the product is a further problem in the case of these processes for 9 microprecipitation. Particularly high-boiling solvents such as dimethylformamide are bound adsorptively at the large surface of the product. Substantial removal, as is necessary for pharmaceutical active compounds, is possible, but very complex.
It is furthermore know to those skilled in the art that the surface areas of microprecipitated products can vary within broad limits since the crystal growth conditions 4 are not adequately determined by the precipitation conditions. Thus, is frequently observed that the surface area of the active compound is not within the tolerances of the specification. In such cases, it is necessary to re-work the product with high additional costs.
Microprecipitation from solution and also fine grinding are an additional process step which requires special technical equipment.
For fine grinding, a grinding unit, usually comprising a jet mill and a complex dust removal system, is necessary to completely remove the pharmacologically highly-effective active compound.
Production plants for microprecipitation require special equipment in order to be able to carry out the mixing, 5 which is preferably carried out, of the solutions in rotor-stator systems, such as the Ultra-Turrax turbine stirrer or in mixer pumps.
Surprisingly, it has now been found that microprecipitation can be carried out in a technically very simple, economically and ecologically very favorable manner.
The invention therefore relates to a process for the preparation of a micronized form of glibenclamide inwhich the active compound particles have a surface area of at least 3 m 2 /g by the BET method, which comprises acidifying a suspension of a sparingly-soluble salt of glibenclamide in water using an acid to give glibenclamride precipitated in microfine form, and to the micronized glibenclamide obtainable by this process.
Special technical equipment is not necessary for the preparation. The process according to the invention can be carried out in a standard stirred kettle.
A further advantage of the process according to the 5 invention is that the surface area of the precipitated active compound can be determined in a reproducible manner by means of the precipitation temperature.
For example, in the preparation of the sodium salt, the surface area is a clear function of the temperature in P 4 o the temperature range from 50 to 940 o Mean surface areas of 14-15 m 2 /g are achieved at 20°C, and a surface area of 2.5-3.0 m 2 /g is achieved at 60°C. The preferably desired surface area in the range from 5-10 m 2 /g is achieved in the temperature range from 35-45 0
C.
Suitable salts of glibenclamide are the salts of the alkali metals lithium, sodium or potassium and the ammonium salt, but preferably the sodium salt.
The mineral acids nitric acid, sulfuric acid, hydrochlor- 15 ic acid or phosphoric acid and the organic acids acetic acid or citric acid are suitable for the precipitation.
Nitric acid or hydrochloric acid is preferably employed.
The pH of the suspension after precipitation is 1.0 to preferably 2.0 to By adding surface-active substances, the cristalline conversion of the glibenclamide salts into glibenclamide microfine can be influenced. Wetting agents which can be employed are physiologically acceptable ionogenic and non-ionogenic substances. Polyoxyethylene stearates, such S 25 as, for example, polyoxyethylene stearate having an average of 50 ethylene oxide units, are preferred. The S concentration is, for example, 0.05-1.0 by weight, preferably 0.1-0.2 by weight, relative to the active compound.
Addition of organic, water-miscible solvents, such as, for example, dimethylformamide or lower alcohols, to the suspensions allows the crystal size and thus the surface ss ~area of the glibenclamide tobe controlled.
-6- The glibenclamide obtainable by the process according to the invention is suitable for the preparation of medicaments.
The preparation according to the invention of micronized glibenclamide having a surface area of at least 3 m 2 /g, preferably 5-10 m 2 by the BET method is explained with reference to the examples below: Example 1 2480 1 of demineralized water are introduced into the kettle, and 62 kg of the Na salt of glibenclamide are introduced with stirring. The temperature of the suspension is adjusted to 40 0 C. 65.4 1 of 2N nitric acid are *i allowed to run in over the course of 30 minutes with Svigorous stirring. The glibenclamide precipitates as a *15 finally divided suspension, which is removed by centrifugation and washed with plenty of water. After drying, the yield is 55.3 kg P 96.5 of theory. The product has a surface area of 6.9 m 2 /g by the BET method. The melting point is 170 0
C.
0 Example 2 1500 ml of water are introduced into the kettle. First 0 0.35 g of polyoxyethylene stearate 50 (®Macrogol) are dissolved therein and subsequently 37.7 g of the Na salt of glibenclamide are suspended therein. The temperature of the suspension is adjusted to 30°C. 40 ml of 2N nitric acid are run in over the course of 30 minutes with vigorous stirring. The pH of the suspension is then pH 2.2. The suspension of microfine glibenclamide is filtered off with suction and carefully washed with water. After drying in vacuo at 60°C, the yield is 33.97 1 97.4% of theory. The surface area by the BET method is 8.7 m 2 /g.
Example 3 75.5 g of the Na salt of glibenclaide are suspended in 2700 ml of demineralized water and 300 ml of methanol.
80 ml of 2N nitric acid are allowed to run in over the nww 7 course of 40 minutes at 300C with stirring. The mixture is stirred for a further 1 hour, and the product is filetered off with suction and washed with plenty of water. After crying in vacuo at 600C, a yield of 67.8 g 96.8 of theory of microfine glibenclamide having a surface area of 4.8 m2/ is obtained.
Water to methanol mixtures in the range of from 5% to 50% by volume can be employed to suspend the Na salt of glibenclamide.
u e** S 0 OS 0 0
VL,
-0 LUaBS j
'$I
A

Claims (13)

1. A process for the preparation of a micronized form of glibenclamide of the formula OCH 3 Cl CONHCH 2 CH 2 SO 2 NHCNH 0 in which the active compound particles have a surface of at least 3 m2/g by the BET method, which comprises acidifing a suspension of a sparingly-soluble salt of glibenclamide in water using an acid to give glibenclamide precipitated in microfine form.
2. The process as claimed in claim 1, wherein the temperature during formation of the microprecipitated glibenclamide is in the range from 50 900C. 6O OSS@ S* *6 0 @006 6
3. 500C. The process of claim 2 wherein said temrperature used is in the range from 300
4. The process as claimed in claim 1, wherein the salt of glibenclamide employed is the lithium, potassium, amonium or sodium salt.
5. The process as claimed in claim 1, wherein the acid employed is a mineral acid, such as nitric acid, hydrochloric acid or sulfuric acid, or a weak organic acid, such as acetic acid or citric acid.
6. The process as claimed in claim 1, wherein the pH value after precipitation of the micronized glibenclamide is pH 1.0-6.0.
7. The process of claim 6 whrein the pH value after said precipitation is pH
8. The process is claimed in claim 1, wherein a pharmacologically acceptable wetting agent is added to the water is a concentration of from 0.05 to 1.0 by weight, relative to the active compound. RA ^s 0 9
9. The process as claimed in claim 8, wherein a polyoxyethylene stearate is added.
The process of claim 9 wherein the polyoxyhethylene stearate contains ethylene oxide units in a concentration of from 0.1 to 0.2 by weight, relative to the active compound.
11. The process as claimed in claim 1, wherein an organic, water-miscible solvent, such as, for example, dimethylformamide or a lower alcohol, is added to the water.
12. The process as claimed in claim 11, wherein a mixture of water with methanol in the range from 5-30 by volume is employed to suspend the Na salt of glibenclamide.
13. Glibenclamide in micronized form obtainable by the process as claimed in any one of claims 1 to 12. DATED this 1st day of November, 1991. HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS THE ATRIUM 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA *S S. s doc01 :AU004230289.WPC
AU42302/89A 1988-10-01 1989-09-28 Process for the micronization of glibenolamide Ceased AU620448B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3833439 1988-10-01
DE3833439A DE3833439A1 (en) 1988-10-01 1988-10-01 METHOD FOR MICRONIZING GLIBENCLAMIDE

Publications (2)

Publication Number Publication Date
AU4230289A AU4230289A (en) 1990-04-05
AU620448B2 true AU620448B2 (en) 1992-02-20

Family

ID=6364187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42302/89A Ceased AU620448B2 (en) 1988-10-01 1989-09-28 Process for the micronization of glibenolamide

Country Status (11)

Country Link
EP (1) EP0362704B2 (en)
JP (1) JPH02149516A (en)
AT (1) ATE89268T1 (en)
AU (1) AU620448B2 (en)
DE (2) DE3833439A1 (en)
ES (1) ES2057043T5 (en)
FI (1) FI894598A (en)
GR (1) GR3020754T3 (en)
NZ (1) NZ230828A (en)
PT (1) PT91835A (en)
ZA (1) ZA897421B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250418T1 (en) * 1998-07-15 2003-10-15 Merck Sante Sas TABLETS CONTAINING A COMBINATION OF GLIBENCLAMIDE AND METFORMIN
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP5183844B2 (en) * 1999-11-03 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー How to treat diabetes
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ES2638977T3 (en) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Improved formulations and procedures for lyophilization and lyophilisates obtained by them
DE102008000351B4 (en) 2008-02-20 2017-08-10 Aristo Pharma Gmbh Process for the preparation of an ebastine-containing granule and a solid pharmaceutical composition, ebastine-containing granules and its use
FR2987268B1 (en) 2012-02-28 2014-07-11 Ammtek LIQUID FORMULATIONS OF HYPOGLYCEMIC SULFAMIDES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD91647A (en) *
DE1301812B (en) * 1965-07-27 1969-08-28 Hoechst Ag Process for the preparation of benzenesulfonylureas
CA889876A (en) * 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
NL7314765A (en) * 1972-10-31 1974-05-02
DE2348334C2 (en) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim New form of preparation of N-4- [2- (5-chloro-2-methoxybenzamido) ethyl] -phenyl-sulfonyl-N'-cyclohexylurea
DD204915B1 (en) * 1981-12-16 1986-05-07 Goldner Richard METHOD OF PREPARING PURE N- (4- (BETA-WELDED BRACKET ON 2-METHOXY-5-CHLORO-BENZAMIDO WELDED BRACKET TO -ETHYL) -PHENYLSULFONYL) -N'-CYCLOHEXYL HARDILLARY
DD248115A1 (en) * 1984-04-11 1987-07-29 Dresden Arzneimittel METHOD OF PREPARING N- (4- (SS-5-CHLORO-2-METHOXY-BENZAMIDO-ETHHYL) -PHENYLSULFONYL) -N'-CYCLOHEXYL HARNON IN FINE DISTRIBUTION
RO89209A2 (en) * 1984-06-12 1986-05-30 Intreprinderea De Medicamente Si Coloranti"Sintofarm",Ro PROCESS FOR OBTAINING GLYBENCLAMIDE

Also Published As

Publication number Publication date
ATE89268T1 (en) 1993-05-15
JPH02149516A (en) 1990-06-08
DE58904332D1 (en) 1993-06-17
FI894598A0 (en) 1989-09-28
EP0362704A1 (en) 1990-04-11
EP0362704B1 (en) 1993-05-12
DE3833439A1 (en) 1991-09-12
EP0362704B2 (en) 1996-08-07
AU4230289A (en) 1990-04-05
PT91835A (en) 1990-04-30
GR3020754T3 (en) 1996-11-30
ZA897421B (en) 1990-06-27
ES2057043T3 (en) 1994-10-16
ES2057043T5 (en) 1996-11-01
FI894598A (en) 1990-04-02
NZ230828A (en) 1991-07-26

Similar Documents

Publication Publication Date Title
DE60129728T2 (en) PROCESS FOR THE PRODUCTION OF NATEGLINIDE CRYSTALS
AU620448B2 (en) Process for the micronization of glibenolamide
EP0179430B1 (en) Aqueous pharmaceutical formulations of piroxicam monohydrate
CA2399844A1 (en) Preparation of glucosamine hydrochloride
GB2176786A (en) A method for optical resolution of phenylacetic acid derivative
CA1301767C (en) Process for preparing cimetidine polymorph b
EP0469541B1 (en) Method of crystallizing phenylalanine
EP0450684B1 (en) A process for the preparation of D-(-)-4-hydroxyphenylglycine and L-(+)-4-hydroxyphenylglycine, starting from D.L.-4-hydroxyphenylglycine
EP1013640B1 (en) Synthesis of guanidines from O-alkylisoureas using a crystal seed
DE1102750B (en) Process for the preparation of a salt of theophylline bases
EP1028106B1 (en) Process for the preparation of guanidine derivatives
PL149466B1 (en) Method of obtaining novel polymorph i of mononoethanolamine n-/2-pyridilo/-2-methyl-4-hydroxy-2h-1,2-benzothiazin-3-carbonamide 1,1-dioxide salt
NZ207514A (en) Preparing solid state dispersions of chlorthalidone(2-chloro-5-(1-hydroxy-3-oxo-isoindolinyl)-benzenesulphonamide)
DE4011956A1 (en) METHOD AND DEVICE FOR PRESENTING STERILE INJECTABLE ANTIBIOTIC POWDERS
JP3930616B2 (en) Method for purifying 2-amino-6-substituted purine
JPH04360863A (en) Production of sodium n-alkylaminoethanesulfonate
WO2001005354A2 (en) Improved process for the preparation of benzenesulfonylureas as oral hypoglycemic agents of the second generation
CA1221367A (en) Fine crystalline isoxicam
JPH0873399A (en) Anhydrous trimagnesium citrate and its production
LU84346A1 (en) NEW N-METHYL-D-GLUCAMINE SALT AND MEDICINE CONTAINING THE SAME
DE3034004A1 (en) SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
EP0367635B1 (en) Process for the preparation of 2-thiocyanomethylthiobenzothiazole
JPS6327477A (en) Production of oxiracetam
EP1110947A1 (en) Process for the purification of creatine
CH691112A5 (en) A process for preparing crystals of a sulfuric acid salt of 3-amino-2-hydroxyacetophenone with high bulk diche and improved flow characteristics.